Royalty Report: Drugs, Drug Discovery, Proteins – Collection: 367562

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 9

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 9

Primary Industries

  • Drugs
  • Drug Discovery
  • Proteins
  • Diabetes Treatment
  • Disease
  • Therapeutic
  • Assay

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 367562

License Grant
Licensor grants to Licensee of Germany the sole and exclusive right and license, with the right to sublicense, under Licensors right title and interest in the Collaboration Technology, including the Licensor Technology and Licensors interest in any Program Technology, to research, develop, make, have made, register, use, sell, offer for sale, have sold and import Collaboration Products in the Field of Use in the Territory.
License Property
Licensor is engaged in the research and development of human pharmaceutical products, and is the owner of certain proprietary compounds, information and know how relating to glucose dependent insulin secretagogues including GPR119 and small molecule agonists thereto, which may be useful in the discovery and development of human pharmaceutical products;

GPR119 Agonist Compounds shall mean compounds that stimulate the human GPR119 receptor activity with an EC50 of less than one (1) micromole per liter (µmol/L) and with an efficacy (Emax) of at least 50% compared to the maximal effect of 100% of the reference compound AR 231453, which has an EC50 < 50nmol/L in this  assay, and exerts its biological effect primarily via this mechanism.

GPR119 is a G-protein coupled receptor (GPCR) that has been implicated as a novel target for the treatment of Type II diabetes.  The activation of GPR119 receptors located in the digestive system stimulates incretins, resulting in increased insulin production, while activation of GPR119 receptors located on pancreatic islet beta cells also stimulates insulin secretion.

Licensor Patent Rights shall mean all Patent Rights filed or to be filed by Licensor arising out of the Licensor proprietary GPR119 Agonist Compounds research program, amended as necessary to include the Patent Rights still arising out of the Licensor proprietary GPR119 Agonist Compounds research program but filed after signature of this  Agreement, and/or the collaborative Research Program with Licensor inventorship only.

Priority Patent Application EP 10162364.3, Filed 07 May 2010 at the European Patent Office
Provisional U.S.App. No. 61/220,133 filed 6/24/2009

Field of Use
The collaboration agreement is to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications.

IPSCIO Record ID: 202851

License Grant
The French Licensor grants back an exclusive, worldwide, irrevocable and perpetual license, including the right to sublicense through multiple tiers of sublicense, under the Licensors Technology and interest in Joint Patents, to research, develop, make, have made, use, sell, have sold, offer for sale and import Collaboration Compounds outside of the Field.
License Property
Proprietary compounds relating to chronic treatment SERCA activators.  Compounds relates to small molecule SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases.
Field of Use
This agreement is for the study of the treatment of type 2 Diabetes, but not on humans.

IPSCIO Record ID: 253904

License Grant
Licensor grants to English Licensee an exclusive, worldwide, right and license, within the Territory and within the Field, to use the Licensor Know-How and Patent Rights and Licensors undivided interest in any Program Intellectual Property that is jointly owned by the Parties, as embodied in or related to any Designated Compound(s), collectively, the Licensed Technology, to research, develop, make, have made and use such Designated Compound to develop Licensed Products, and, to make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products.
License Property
The parties pursue a collaborative screening process to identify compounds exhibiting a high degree of chemical binding activity to targets designated by Licensee from among the Licensor libraries of mass-encoded small molecule compounds and which have activity in bioassays or functional assays.

The know-how and patents include screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Licensed Product(s) means any product which includes a Designated Compound or any derivatives, improvements and components thereof; and the development, manufacture, use, or sale.

Licensor Library includes ALIS, the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to the Licensor that is used to identify multiple classes of chemical ligands against target protein.

Field of Use
The Field means the diagnosis or treatment of any disease in humans.  The Licensee is identifying potential pharmaceutical products for treatment of certain human diseases and is identifying compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

IPSCIO Record ID: 299264

License Grant
By this agreement, Licensor shall provide the resources to Licensee and conduct activities under the Research Program. Licensor shall review data and information regarding the Collaboration Target provided by Licensee and derived from the UIL by Licensor, based on such data and information and using the Licensor Technology, design Daughter Libraries; and supply all lead chemistries and synthesize compounds.

Licensee will utilize Licensor Technology for its drug discovery activities under Licensee know-how concerning the identification and characterization of novel small molecule inhibitors.

In addition to Licensees non-exclusive right to use Licensor Technology as necessary to conduct activities under the Research Program, Licensor grants an exclusive, worldwide license, with the right to sublicense to use such Licensor Technology as is necessary to make, have made, use, have used, sell, have sold, import and export Active Compounds, Development Compounds and/or Products in the Territory.

License Property
Licensor has developed, licensed and/or owns certain drug discovery technology and intellectual property rights, including chemical library design software, multi-parallel synthesis and purification methods, chemical libraries suitable for high throughput biological screening assays and medicinal chemistry.

Initial target is Type 3 Phosphodiesterases.

Alternative targets are DNA Polynucleotide kinase (DNA-PK), Poly (ADP-ribase) polymerase (PARP), and, Modulators of the interaction between the G-beta subunit of the G-protein and beta-adrenergic receptor kinase (gB-BARK)

Field of Use
The research focus is for development as therapeutics for treatment of obesity and other diseases in humans.

IPSCIO Record ID: 249719

License Grant
Licensor grants the Japanese Licensee an exclusive, worldwide, right and license, within the Territory, to use the Licensor Know-How and Patent Rights and Licensors undivided interest in any Program Intellectual Property and Joint Program Patent Rights, as embodied in or related to any Designated Compounds, to research, develop, make, have made and use such Designated Compound to develop Licensed Products and to make, have made, use, distribute for sale, promote, market, offer for sale, sell, have sold, import and export Licensed Products.

This agreement includes non-exclusive terms as well.

License Property
The licensed property includes
(a) the Ne0Morph Screening Library,
(b) the NeoMorph Focused Libraries,
(c) ALIS and QSCD,
(d) the Candidate Compound A,
(e) the Candidate Compound B,
(d) the Candidate Compound C, together with, where applicable, any analogs, derivatives, fragments, sub-cellular constituents or expression products thereof and
(e) any other tangible materials provided by Licensor to Licensee for use in the conduct of the Program, which is Controlled by Licensor, primarily relates to a Designated Compound or Licensed Products, whether or not patentable.

NeoMorph Chemistry means the process, proprietary to Licensor, of forming libraries and sub-libraries of discrete compounds by coupling a broad set of diverse cores with diverse sets of building blocks employing proprietary mass-coding algorithms.

NeoMorph Focused Libraries means those compounds synthesized by Licensor derived from Active Compounds identified by Licensee in bioassays or functional assays NeoMorph Screening Library means the entire collection of libraries consisting of mass-encoded small molecule organic compounds owned by Licensor and developed with NeoMorph Chemistry, comprising at least 10,000,000 different compounds.

Licensee is interested in identifying potential pharmaceutical products for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets. Licensor has certain technology and know-how, including screening processes of libraries of mass-encoded small molecule compounds, relating to the identification, discovery, validation and optimization of novel compounds which may be useful for development of novel therapeutics employing targets implicated in a disease process.

Field of Use
The Licensees intended use is for treatment of certain human diseases and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets.

The Field means treatment of any disease in humans.

IPSCIO Record ID: 204371

License Grant
Licensor grants to the French Licensee a non-exclusive, non-sublicensable, license solely to use the materials for the evaluation during the Evaluation Period.

Licensor grants an exclusive, except as to Licensor license, with the right to sublicense solely to Licensees affiliates, under the Research Technology and Licensors interest in Joint Patents, solely to perform the Research Collaboration Plan during the Research Collaboration Term; and on a Selected Compound-by-Selected Compound basis, effective upon Licensees selection of each Selected Compound, an exclusive license, with the right to sublicense through multiple tiers of sublicense, under the Licensed IP Rights and Licensors interest in Joint Patents, to research, develop, make, have made, use, sell, have sold, offer for sale and import such Selected Compound and Products containing or comprising such Selected Compound in the Field in the Territory.

License Property
Proprietary compounds relating to chronic treatment SERCA activators.  Compounds relates to small molecule SERCA2b modulators for the treatment of type 2 diabetes and other metabolic diseases.
Field of Use
This agreement is for the study of the treatment of type 2 Diabetes, but not on humans.

IPSCIO Record ID: 289242

License Grant
Licensor hereby grants to Japanese Licensee, under the Licensed Technology, an exclusive, royalty-bearing license, with the right to grant sublicenses, to develop, have developed, make, have made, use, sell, offer for sale and import Licensed Products within the Licensed Field in the Licensee Territory.
License Property
Licensed Product shall mean
          (i)   any Clinical Candidate (as defined in the Collaboration Agreement);
          (ii)  any compound (a) which is identified, developed or discovered by Licensee using Licensed Technology and (b) which acts through activation of the insulin signal transduction pathway for the treatment of diabetes mellitus or insulin resistance in humans; and
          (iii) any compound which is an analog, homolog or chemical modification of a compound described in clause (i) or (ii) and which acts through activation of the insulin signal transduction pathway for the treatment of diabetes mellitus or insulin resistance in humans.

Licensed Technology shall mean the Licensed Patent Rights and the Licensed Know-How.

Licensed Patent Rights shall mean all of (i) Licensors interest in any patents and patent applications (including any divisions, continuations-in-part, reissues, extensions, renewals, supplementary protection certificates and foreign counterparts thereof) covering inventions made in the course of the Research Program (the Research Program Patents) and (ii) other patents and patent applications (including any divisions, continuations-in-part, reissues, extensions, renewals, supplementary protection certificates and foreign counterparts thereof) owned or Controlled by Licensor, but only to the extent such other patents and patent applications are necessary or useful for Licensee for the manufacture, use, sale, offer for sale or import of Licensed Products which are covered by the Research Program Patents.

Field of Use
License is for the development of a Type II diabetes drug.  The molecular fingerprinting is a family of small molecules that have demonstrated they can bind to and activate the insulin receptor to lower blood glucose levels in diabetes patients.

IPSCIO Record ID: 279355

License Grant
License to Commercialize Collaboration Compounds –  Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensors interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.

License to Compounds (Other than Collaboration Compounds)  Derived from Licensee Compounds – Licensor grants to Licensee a worldwide, exclusive license, with the right to sublicense, under the Licensor IP and Licensors interest in the Collaboration IP, to make, have made, use, sell, offer to sell and import Collaboration Compounds, and/or Collaboration Products based on such Collaboration Compounds, for any and all uses and indications in the Licensee Field.

License Property
Collaboration Product shall mean a pharmaceutical product containing a Collaboration Compound that is sold by Licensee or Licensor, or their respective Sublicensees or Affiliates.  It is understood that, in the event any Collaboration Compound is sold for therapeutic purposes, such Collaboration Compound shall be deemed a Collaboration Product and shall be subject to milestones and royalties as set forth in this Agreement.

Collaboration Compound shall mean a Licensor Compound or a Non-Exclusive Compound or a compound that is derived, directly or indirectly, from a Licensee Compound, Licensor Compound, or Non-Exclusive Compound; in each case, that modulates the biological activity of a Collaboration Target at a level of potency to be established by the JRC.  A compound shall be deemed to have been derived directly from another compound if it (i) is the result of a chemical modification made to such a compound, (ii) is otherwise obtained from a chemical synthesis program based on one or more such compounds, (iii) is based on proprietary structure-activity data obtained from the testing of one or more such compounds, or (iv) is specifically or generically within the scope of one or more claims of any patent application or patent filed by Licensor or Licensee or their Affiliates to protect any compound in category (i), (ii) or (iii) above.  A compound shall be deemed to have been derived indirectly from another compound if it is the result of a series of iterations of any or all of (i) through (iv) above.  For purposes of clarity, any compound synthesized in the course of the Collaboration and based on a Licensee Compound, Licensor Compound, or Non-Exclusive Compound which is active against a Collaboration Target at the level of potency established by the JRC shall be deemed a Collaboration Compound.  Joint Research Committee or “JRC” shall mean the entity organized to manage the scientific implementation of the Collaboration.

Licensee IP shall mean Licensee Patents and Licensee Know-how.

Collaboration IP shall mean Collaboration Patents and Collaboration Know-how.  Collaboration IP shall not include Licensor IP or Licensee IP.

Licensor IP shall mean Licensor Patents and Licensor Know-how.  Licensor IP shall not include any intellectual property owned or licensed by Licensor or its Affiliates relating to the ECLiPSâ„¢ technology (i.e., the creation or use of encoded combinatorial libraries or any tag and/or marker compounds).

Licensee Patents shall mean all Patents in the Territory Controlled by Licensee or its Affiliates as the effective date, or any other Patent Controlled by Licensee during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.

Licensor Patents shall mean all Patents in the Territory Controlled by Licensor or its Affiliates as the Effective Date, or any other Patent Controlled by Licensor during the Term; in each case, necessary for the discovery, development, manufacture, importation or use of one or more Collaboration Compounds and/or the development, manufacture, use, sale, importation or commercialization of corresponding Collaboration Products.

Collaboration Patents shall mean (i) all patents and patent applications claiming any invention or discovery which was conceived or reduced to practice during the Collaboration Term and in the course of the Collaboration, by employees or agents of Licensee, Licensor or any of their respective Affiliates, either alone or jointly (including, without limitation, the synthesis and composition of matter of any Collaboration Compound, or method of use thereof; and (ii) any divisions, continuations, continuations-in-part, reissues, reexaminations, extensions or other governmental actions which extend any of the subject matter of the patent applications or patents in (i) above, and any substitutions, confirmations, registrations, revalidations, or additions of any of the foregoing, in each case, which is owned or Controlled, in whole or part, by license, assignment or otherwise by Licensor or Licensee during the term of this Agreement; provided, however, that Collaboration Patents shall not include any Licensee Patents or Licensor Patents.

Licensor Compound shall mean any compound brought to the Collaboration by Licensor, which is Controlled by Licensor at or after the Effective Date, and which is proprietary to Licensor by virtue of being within the Licensor IP.

Field of Use
The primary objective of the alliance is to identify active molecules and bring them forward to clinical proof of concept, yielding novel candidates for drug development in various therapeutic areas.

Licensor Field shall mean, with respect to each Collaboration Compound for which Licensor has received approval to develop pursuant, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

Licensee Field shall mean, with respect to each Collaboration Compound, all human and animal disorders and diseases treated by modulation of a Collaboration Target by such Collaboration Compound.

IPSCIO Record ID: 329676

License Grant
For the license grant for Exclusive Screens Licensor grants an exclusive right and license, under the Technology, Patents and Know-How, to use and practice the Exclusive Screens, including, without limitation, the right to grow sufficient amounts of Materials provided by Licensor to Licensee.

For the license grant for Non-Exclusive Screens, License grants an exclusive right and license, under the Technology, Patents and Know-How, to use and practice Non-Exclusive Screens, including, without limitation, the right to grow sufficient amounts of Materials provided by Licensor to Licensee, during the term of the Research Programs, but in no event for less than nine months after Licensee receives Materials and other information from Licensor identifying and enabling Licensee to use such Non-Exclusive Screen.

License Property
Licensor has the exclusive rights to certain technology involving the transfection and expression of G-protein- coupled receptors into yeast.  Licensor exploits similarities between the yeast and human genome to identify new drug discovery targets.

The Autocrine System shall mean that part of Licensors Technology whereby any yeast cells into which human Receptors have been inserted and grow in response to compounds produced and secreted by the same yeast cells.

Compound shall mean any Lead Compound or any Analog of any Lead Compound.

Receptor shall mean any human, G-protein-coupled, seven transmembrane receptor (including, without limitation, genes, vectors and cDNAs), and shall include any Licensee Receptor or Other Receptor.

Licensee Receptor shall mean a Receptor which is proprietary to Licensee and is provided by Licensee to Licensor for use in the Research Programs, or a Receptor which is proprietary to Licensee and is cloned or obtained by Licensor pursuant to research performed under the Research Programs, or a Receptor provided by Licensee to Licensor for use in the Research Programs which is deemed to be a Licensee Receptor.

Technology shall mean all inventions, improvements, discoveries, claims, formulae, processes, trade secrets, technologies, Patents and Know-How owned by Licensor or to which Licensor has the rights to grant licenses or sublicenses, and relating to or derived from Licensors yeast-based, human G-protein-coupled receptor technology, or the Research Programs.

The Patents are titled
Expression of G Protein Coupled Receptors in Yeast, Yeast-Based Peptide Libraries for identification of G Protein-Coupled Receptor Agonists and Antagonists, and, Functional Expression of Mammalian Adenylyl cyclase in Yeast.

Field of Use
The field of use is screening assays.

Licensee recognizes that the technology represents a valuable source of development of screening assays for the discovery of potential products for manufacture, use and sale in the Territory.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.